Bellevue Group AG Acquires 56,500 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Bellevue Group AG grew its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 4.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,444,109 shares of the company’s stock after purchasing an additional 56,500 shares during the period. Bellevue Group AG’s holdings in SI-BONE were worth $20,189,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Harbor Capital Advisors Inc. grew its holdings in SI-BONE by 222.5% during the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock worth $8,674,000 after buying an additional 428,110 shares in the last quarter. American Century Companies Inc. grew its stake in shares of SI-BONE by 22.8% in the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after acquiring an additional 368,637 shares in the last quarter. Champlain Investment Partners LLC lifted its position in shares of SI-BONE by 14.7% during the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after purchasing an additional 358,821 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in SI-BONE by 24.7% during the second quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock worth $17,448,000 after purchasing an additional 267,100 shares during the last quarter. Finally, Impax Asset Management Group plc grew its position in SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock worth $10,604,000 after purchasing an additional 221,604 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

SI-BONE Stock Up 2.2 %

NASDAQ:SIBN opened at $13.56 on Friday. The business has a fifty day simple moving average of $13.48 and a two-hundred day simple moving average of $14.14. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.70.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SIBN. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research note on Wednesday, November 20th. Truist Financial upped their price objective on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley lowered their target price on SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $23.00.

Insider Transactions at SI-BONE

In related news, insider Anthony J. Recupero sold 3,937 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.60, for a total value of $49,606.20. Following the completion of the transaction, the insider now directly owns 228,554 shares of the company’s stock, valued at approximately $2,879,780.40. This trade represents a 1.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Anshul Maheshwari sold 2,439 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the sale, the chief financial officer now directly owns 194,623 shares in the company, valued at $2,467,819.64. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,093 shares of company stock worth $299,558. 3.90% of the stock is owned by company insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.